February 3, 202300:00 AM – 00:00 PM EST

Who: Wiskott-Aldrich Foundation, Center for Drug Evaluation and Research - U.S. Food and Drug Administration

What: Externally-Led Patient-Focused Drug Development (EL-PFDD) Event

{details here}

When: February 2, 2023

{time – agenda}

Where: {link to virtual event}

Why: {what are the desired outcomes?}

Are there any graphics assets available for the site?

What is an Externally-Led Patient-Focused Drug Development meeting?

Externally-led Patient Focused Drug (EL-PFDD) meetings give the Food and Drug Administration (FDA) and other key stakeholders — including medical product developers, health care providers, and federal partners — an important opportunity to hear directly from patients, their families, caregivers, and patient advocates about the symptoms that matter most to them, the impact the disease has on patients’ daily lives, and patients’ experiences with currently available treatments. This input can inform FDA’s decisions and oversight both during drug development and during their review of a marketing application for a new drug.

Click here to learn more about Externally-Led Patient-Focused Drug Development meetings.